AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Farxiga / Forxiga (dapagliflozin) by Year
Farxiga / Forxiga (dapagliflozin) — Emerging Markets YoY CER (%) (%)
AstraZeneca Farxiga / Forxiga (dapagliflozin): 18.0% in FY2025, down 17.0 pts from a year earlier.
Latest, FY2025
18.0%
Period ended Dec 31, 2025
Change on a year earlier
-17.0 pts
35.0% in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Farxiga | 8,400 | 10 | 9 | 1,730 | (1) | 3,324 | 17 | 18 | 2,941 | 12 | 8 | 405 | (3) | (3)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Farxiga / Forxiga (dapagliflozin) — Emerging Markets YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.0% | -17.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 35.0% | -5.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 40.0% | -7.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 47.0% | -23.0 pts | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 70.0% | +15.0 pts | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 55.0% | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Farxiga / Forxiga (dapagliflozin) (%), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-farxiga-em-cer-yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.